🧬 Expanding Access to Affordable Cancer Treatment
🔬 Biocon Biologics Ltd, a subsidiary of Biocon Ltd, announced that the U.S. FDA has approved Jobevne™ (bevacizumab-nwgd), a biosimilar to Avastin®, marking its seventh biosimilar approval in the U.S. and further strengthening its oncology portfolio.
🌱 What is Jobevne™?
A VEGF inhibitor, Jobevne™ targets blood vessel growth (angiogenesis) in tumors — a vital therapy in treating several cancers including:
- Metastatic colorectal cancer
- Advanced non-small cell lung cancer
- Recurrent glioblastoma
- Cervical, renal cell, and ovarian cancers
🌍 Already approved in Europe and Canada as ABEVMY™, this approval reflects Biocon’s scientific depth and global biosimilar footprint. In the U.S. alone, bevacizumab sales touched $2.0B in 2023.
🗣️ Shreehas Tambe, CEO & MD, said:
“This is a significant milestone… and underscores our commitment to expanding access to high-quality, affordable biologics.”
💡 Biocon Biologics serves over 5 million patients annually, with 20+ biosimilar assets in development across oncology, immunology, diabetes, and more.
#BioconBiologics #Jobevne #FDAApproval #Biosimilars #Oncology #AffordableHealthcare #BiotechIndia #ScienceNews #SciFocus
